Mindray Statement on Masimo Lawsuit Against Mindray
SHENZHEN, China, Jan. 7, 2013
SHENZHEN, China, Jan. 7, 2013 /PRNewswire-FirstCall/ -- Mindray Medical
International Limited ("Mindray," NYSE: MR), a leading developer, manufacturer
and marketer of medical devices worldwide, today announced a statement on
Masimo Corporation's lawsuit against Mindray.
On December 21, 2012, Masimo Corporation ("Masimo") brought an action in the
United States District Court for the Central District of California against
Mindray DS USA Inc. and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Masimo alleges that Mindray DS USA, Inc.'s U.S. Beneview pulse oximeters and
sensors infringe its nine asserted patents relating to pulse oximeters and
sensors, and that Shenzhen Mindray Bio-Medical Electronics Co., Ltd breached
its Purchase and License Agreement dated November 13, 2002, as amended, by
failing to use best efforts to promote adoption of Masimo's oximeter
technology. In addition to monetary damages, Masimo is seeking injunctive
relief preventing further sale of Beneview products incorporating Mindray
oximetry boards in the United States.
Mindray intends to vigorously defend the actions.
We are a leading developer, manufacturer and marketer of medical devices
worldwide. We maintain our global headquarters in Shenzhen, China, U.S.
headquarters in Mahwah, New Jersey and multiple sales offices in major
international markets. From our main manufacturing and engineering base in
China, we supply through our worldwide distribution network a broad range of
products across three primary business segments, namely patient monitoring and
life support, in-vitro diagnostic, and medical imaging systems. For more
information, please visit http://ir.mindray.com.
For investor and media inquiries please contact:
In the U.S:
Western Bridge, LLC
Mindray Medical International Limited
SOURCE Mindray Medical International Limited
Press spacebar to pause and continue. Press esc to stop.